Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICARUS BREAST 2
2023-505925-15-00Phase 2Authorised
- Sponsor
- Gustave Roussy
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of patritumab deruxtecan in breast cancer (2 arms), sponsored by Gustave Roussy. Primary endpoints: Safety and tolerability of HER3-DXd and Anti-tumor activity of HER3-DXd. Planned start Jan 2024; status: authorised.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-505925-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505925-15-00.